HC Wainwright Predicts BioCardia’s Q1 Earnings (NASDAQ:BCDA)

BioCardia, Inc. (NASDAQ:BCDA) – Equities researchers at HC Wainwright issued their Q1 2026 earnings estimates for BioCardia in a report released on Thursday, March 26th. HC Wainwright analyst J. Pantginis expects that the company will post earnings per share of ($0.17) for the quarter. The consensus estimate for BioCardia’s current full-year earnings is ($3.52) per share. HC Wainwright also issued estimates for BioCardia’s Q2 2026 earnings at ($0.18) EPS, Q3 2026 earnings at ($0.17) EPS and Q4 2026 earnings at ($0.18) EPS.

BioCardia (NASDAQ:BCDA) last posted its earnings results on Tuesday, March 24th. The company reported ($0.06) EPS for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.14.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of BioCardia in a research report on Wednesday, January 21st. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $25.00.

BioCardia Price Performance

BioCardia stock opened at $1.16 on Friday. BioCardia has a 12-month low of $1.00 and a 12-month high of $3.20. The firm’s fifty day moving average price is $1.23 and its 200 day moving average price is $1.34. The company has a market capitalization of $12.69 million, a price-to-earnings ratio of -0.90 and a beta of 0.60.

Institutional Investors Weigh In On BioCardia

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Cetera Investment Advisers bought a new position in shares of BioCardia in the 2nd quarter valued at about $40,000. DRW Securities LLC bought a new stake in BioCardia during the fourth quarter worth about $72,000. Finally, Geode Capital Management LLC boosted its position in BioCardia by 70.4% during the fourth quarter. Geode Capital Management LLC now owns 66,003 shares of the company’s stock valued at $83,000 after purchasing an additional 27,263 shares during the last quarter. 20.57% of the stock is owned by institutional investors.

BioCardia Company Profile

BioCardia, Inc is a clinical-stage biotechnology company dedicated to developing novel cell-based therapies for patients with cardiovascular disease. The company’s core focus lies in advancing regenerative medicine approaches that address both chronic heart failure and acute myocardial infarction. BioCardia leverages proprietary delivery technologies to optimize the targeted administration of therapeutic cells directly into the heart muscle.

The company’s flagship products include the Helix Transendocardial Delivery System and the CardiAMP Cell Therapy System.